ADLT™ and Getting a handle on API Inventory
Recently, I spoke to a Pharma Company and asked them how much visibility they had into the manufacturing of APIs and other raw ingredients. The representative responded: “We don’t have any visibility into the API’s”.
As with the rest of the supply chain, this lack of visibility has a significant impact on inventory levels and the ability to anticipate shortages along with meeting the requirements of certain regulatory agencies to keep a minimum inventory on hand.
While not required as part of the serialization initiatives, it would behoove our industry to try and close the loop on the entire process from raw materials to patients using the medication… Read More